EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Immunovant Inc (IMVT) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Immunovant Inc $4.09, price $33.62, upside -87.8%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US45258J1025

II Immunovant Inc logo Thin data Sep 28, 2026

Immunovant Inc

IMVT · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $4.09 · Strongly overvalued (−87.8%)
!Quality 23/100
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 12/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
Watch Immunovant Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$44.96 $3.38 Fair Value $4.09 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range $3.38 – $44.96 · fair‑value band $2.70 – $5.11 · the $33.62 price screens above the $4.09 fair value. Dashed = 300-day average. As of Sep 28, 2026.

Follow Immunovant in your weekly email

Every Wednesday you see whether Immunovant is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.

Show more

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Stock analysis

Immunovant Inc (IMVT) currently trades at $33.62, while our model-based Fair Value estimate is $4.09, 87.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $2.70 (bear) to $5.11 (bull), the price of $33.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Immunovant Inc reported revenue of $0 in FY2026 versus $0 in FY2022. Reported net income was −$506M in FY2026.

Key figures

Market cap $6.9B · EPS (TTM) $−2.81 · Return on equity −80.1% · Return on assets (EBIT) −46.8% · Free cash flow −$407M · Net cash $902M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, IMVT screens richer than that median.

Fair Value models

Bear $2.70 Fair Value $4.09 Bull $5.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $2.06 $2.77 $4.13 51
All 1 models by family
Asset-Based
NCAV (Graham) $2.06 $2.77 $4.13 51

Open the full fair value analysis →

Notify me when IMVT reaches fair value

Put IMVT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 32 · Market factors (momentum, volatility) 66

Profitability 0
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 20
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 42
Calm price path (market factor)
Momentum 73
Price trend over the last 3–12 months (market factor)
52W Momentum 80
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

IMVT screens overvalued: fair value 88% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (88 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Immunovant Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −87.8% · Bottom 25%
Profitability
Return on assets −46.7% · Bottom 25%
Operating margin (TTM) 0.0% · Above median
Growth and dividend
Revenue growth 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.07× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Immunovant Inc · Fair Value
$4.09 −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Immunovant Inc Fair Value". https://www.fairvalue-calculator.com/stock/IMVT

Frequently asked questions

Is Immunovant Inc (IMVT) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of $4.09 versus a price of $33.62, about −88% upside (overvalued).
What is the fair value of IMVT?
Our model-based fair value for Immunovant Inc is $4.09 (as of Sep 28, 2026), built from audited fundamentals. The current price: $33.62.
What is the quality score of IMVT?
Immunovant Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunovant Inc (IMVT)?
Our model-based price target is the fair value of $4.09 (as of Sep 28, 2026) from 1 valuation models. Cautious scenario $2.70, optimistic scenario $5.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Immunovant Inc stock forecast for 2026?
Our models put fair value at $4.09, about −88% upside versus a price of $33.62 (overvalued). Cautious scenario $2.70, optimistic scenario $5.11. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Immunovant Inc (IMVT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunovant Inc it is $4.09 per share (as of Sep 28, 2026), against a price of $33.62. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Immunovant Inc stock overvalued or undervalued in 2026?
As of Sep 28, 2026, IMVT trades above its calculated fair value: price $33.62, fair value $4.09, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMVT?
No. The price is what the market pays today ($33.62); the fair value is what the company's own numbers justify ($4.09). For Immunovant Inc the two are $29.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunovant Inc worth?
The market values Immunovant Inc at about $6.9B (market capitalisation, as of Sep 28, 2026). Per share that is $33.62; our models calculate a fair value of $4.09 per share.
What do the bullish and bearish scenarios say about IMVT?
Our models span a range for Immunovant Inc: cautious scenario $2.70, base $4.09, optimistic $5.11 per share (as of Sep 28, 2026, price $33.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Immunovant Inc (IMVT)?
Balance-sheet figures for Immunovant Inc (as of Sep 28, 2026): return on equity −80.1%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is IMVT from its 52-week high?
Immunovant Inc trades at $33.62, about 25% below its 52-week high of $44.96 and 109% above the low of $16.08 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $4.09 is for.
Which stocks are comparable to Immunovant Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunovant Inc stock attractive at the current price?
The data as of Sep 28, 2026: price $33.62, calculated fair value $4.09 (−88%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMVT calculated?
We run Immunovant Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Immunovant Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunovant Inc (IMVT)?
The closing price on Oct 2, 2026 was $33.62. Our model-based fair value is $4.09, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunovant Inc right now?
The price sits above even our optimistic bull case ($5.11). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.70 to $5.11) leaves room in how you read the outcome.

Key figures of Immunovant Inc

How large is the market capitalisation of Immunovant Inc (IMVT)?
The market capitalisation of Immunovant Inc is $6.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Immunovant Inc (IMVT)?
Earnings per share at Immunovant Inc are $−2.81. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Immunovant Inc (IMVT)?
The return on equity (ROE) of Immunovant Inc is −80.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Immunovant Inc (IMVT)?
On an EBIT basis the return on assets of Immunovant Inc is −46.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Immunovant Inc (IMVT) generate?
The free cash flow of Immunovant Inc is −$407M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Immunovant Inc (IMVT) hold?
Immunovant Inc holds more cash than debt, $902M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Immunovant Inc in the live analysis

One click puts Immunovant Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.